Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 14/04/2026 am IST			5-day change	1st Jan Change
50.68 ^USD	-0.55%		+3.92%	+71.85%

02:35pm	Os Therapies Inc Announces Appointment of Robert "Bob" S. Langer as Strategic Advisor Board	CI
14/04	Trump officials consider ophthalmologist Hemmati for top vaccine post, reports say	RE

Moderna Falls As FDA Vows To Impose New Vaccine Rules

Published on 12/02/2025 at 02:02 am IST

MT Newswires

MODERNA, INC.

-0.55%

Moderna (MRNA) falls after the Food and Drug Administration said in a memo last week that it would place new restrictions on which vaccines hit the market. Bloomberg News reporter Gerry Smith discussed the story on "Bloomberg Markets" with Katie Greifeld.

Bloomberg videos, provided by MT Newswires

Latest news about Moderna, Inc.

02:35pm	Os Therapies Inc Announces Appointment of Robert "Bob" S. Langer as Strategic Advisor Board	CI
14/04	Trump officials consider ophthalmologist Hemmati for top vaccine post, reports say	RE
09/04	US CDC delays publishing report showing COVID vaccine benefits, WaPo reports	RE
09/04	US CDC delays publishing report showing Covid-19 vaccine benefits, Washington Post reports	RE
07/04	RBC Adjusts Price Target on Moderna to $35 From $30, Maintains Sector Perform Rating	MT
01/04	Barclays Adjusts Price Target on Moderna to $48 From $25, Maintains Equalweight Rating	MT
01/04	Rare disease advocacy group urges Trump administration to restore FDA clarity	RE
23/03	Arbutus Biopharma 2025 Net Loss Narrows as Revenue Rises	MT
23/03	Pyxis Oncolog Appoints Heather Knowles as Senior Vice President, Head of Global Clinical Operations	CI
18/03	Deutsche Bank Adjusts Moderna Price Target to $45 From $28, Maintains Hold Rating	MT
17/03	Moderna says CEO Stéphane Bancel's 2025 total compensation was $19.9 million - SEC filing	RE
17/03	US Health Secretary Kennedy's vaccine actions and policy positions	RE
13/03	GSK gets US FDA approval for expanded use of RSV vaccine	RE
10/03	Moderna, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-10-2026 09:30 AM
05/03	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT

Chart Moderna, Inc.

Duration

Period

MRNA: Dynamic Chart

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

4,700

Sector

Pharmaceuticals

More about the company